Corporate venture capital is increasingly becoming a structural part of biopharma ownership and follow-on funding, according to commentary featuring UK and Nordic investor perspectives. British Business Bank committed £75 million to Molten Ventures’ new Growth Fund, targeting £350 million to back UK and European technology companies from Series B onward. Experts cited data that a large share of US biopharma IPOs and pharma acquisitions since 2022 included corporate investors on the cap table.